Joseph Zhao, MBBS, MRCP

Hospital Resident

DownloadHi-Res Photo

About

Titles

Hospital Resident

Biography

Dr Joseph Zhao is an Internal Medicine Resident at Yale New Haven Hospital and Dean’s Fellow at the Yong Loo Lin School of Medicine, National University of Singapore (NUS). He obtained his medical degree from NUS in 2022, graduating on the Dean’s List, and was subsequently elected to the Membership of the Royal Colleges of Physicians of the United Kingdom in 2026.

Last Updated on June 12, 2026.

Departments & Organizations

Internal Medicine

Education & Training

Internal Medicine Resident: Yale New Haven Hospital

MBBS: National University of Singapore

Research

Publications
- 53 Publications
- 2,257 Citations
- 3 Yale Co-Authors
See All Publications

Publications

Featured Publications

Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases
Zhao J, Ong C, Srivastava S, Chia D, Ma H, Huang K, Sheng T, Ramnarayanan K, Ong X, Tay S, Hagihara T, Tan A, Teo M, Tan Q, Ng G, Tan J, Ng M, Gwee Y, Walsh R, Law J, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh B, Hong J, Tay R, Teo C, Dings M, Bijlsma M, Lum J, Mathur S, Pietrantonio F, Blum S, van Laarhoven H, Klempner S, Yong W, So J, Chen Q, Tan P, Sundar R. Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases. Gastroenterology 2024, 167: 1384-1398.e4. PMID: 39147169, DOI: 10.1053/j.gastro.2024.08.007.
Peer-Reviewed Original Research
Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Zhao J, Yap D, Chan Y, Tan B, Teo C, Syn N, Smyth E, Soon Y, Sundar R. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2021, 40: 392-402. PMID: 34860570, DOI: 10.1200/jco.21.01862.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords
Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Ong C, Zhao J, Liu Y, Srivastava S, Chia D, Quek Y, Fan X, Ma H, Huang K, Sheng T, Tan Q, Ng G, Tan J, Lee J, Loo L, Chong L, Ong X, Tay S, Hagihara T, Tan A, Joseph C, Teo M, Hendrikson J, Chong C, Guo W, Chia C, Wong J, Seo C, Cai M, Tay Y, Sim K, Tay R, Walsh R, Guaglio M, Morano F, Teh M, Lum H, Lim T, Vermeulen L, Bijlsma M, Lenos K, Klempner S, Yeong J, Yong W, Pietrantonio F, Tan P, Sundar R. Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis. Clinical Cancer Research 2025, 31: 2515-2529. PMID: 40299767, PMCID: PMC12163601, DOI: 10.1158/1078-0432.ccr-24-3780.
Peer-Reviewed Original Research
MeSH Keywords
Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Nasca V, Zhao J, Ros J, Lonardi S, Zwart K, Cohen R, Fakih M, Jayachandran P, Roodhart J, Derksen J, Intini R, Bergamo F, Mazzoli G, Ghelardi F, Ligero M, Jonnagaddala J, Hawkins N, Ward R, Wankhede D, Brenner H, Hoffmeister M, Vitellaro M, Salvatore L, Gallois C, Laurent-Puig P, Cremolini C, Overman M, Taieb J, Tougeron D, Andre T, Kather J, Sundar R, Carmona J, Elez E, Koopman M, Pietrantonio F. Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors. Journal For ImmunoTherapy Of Cancer 2025, 13: e010598. PMID: 39929672, PMCID: PMC11815414, DOI: 10.1136/jitc-2024-010598.
Peer-Reviewed Original Research
MeSH Keywords
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer
Choo J, Zhao J, Lau M, Raimondi A, Yim W, Ranganathan S, Zhu K, Tan C, Chin H, Teo C, Fong K, Tay R, Lee J, Loo L, Manca P, Morano F, Prisciandaro M, Randon G, Damonte C, Micarelli E, Leoni G, Scarselli E, Lonardi S, Cremolini C, Marmorino F, Lim J, Neo Z, Wee F, Chong L, Joseph C, Balachander A, Lim D, Hwang Y, Renia L, Biswas S, Tan D, Yeong J, Sundar R, Pietrantonio F. Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer. Nature Communications 2026, 17: 6294. PMID: 42034603, PMCID: PMC13376910, DOI: 10.1038/s41467-026-72204-2.
Peer-Reviewed Original Research

2026

Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies
Chua W, Zhao J, Lee C, Su Y, Lee S, Lee J, Tai D, Tan S, Sundar R, Ng K. Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies. JNCI Cancer Spectrum 2026, pkag084. PMID: 42627365, DOI: 10.1093/jncics/pkag084.
Peer-Reviewed Original Research
Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.
Zhao J, Lee C, Chan A, Blum S, Li C, Ma H, Luo W, Srivastava S, Lum H, Tay S, Kwon W, Park S, Joseph C, Chong L, Jung M, Sridhar S, Pelissier A, Bhatt N, Lee J, Dai Y, Loo L, Tan A, Hagihara T, Wee F, Chia D, Sim K, Teh M, Nakayama I, Xu J, Ng M, Walsh R, Yeong J, Jeyasekharan A, Grabsch H, So J, Yong W, Vazquez-Garcia I, Bod L, Klempner S, Shitara K, Janjigian Y, Tan P, Rodríguez Martínez M, Rha S, Sundar R. Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer. Clinical Cancer Research 2026, of1-of14. PMID: 42565557, DOI: 10.1158/1078-0432.ccr-26-1382.
Peer-Reviewed Original Research
Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma
Zhao J, Pietrantonio F. Long-term survival outcomes with immune checkpoint inhibition in PD-L1 low or intermediate expressing gastroesophageal adenocarcinoma. Annals Of Oncology 2026, 37: 754-755. PMID: 41887944, DOI: 10.1016/j.annonc.2026.02.016.
Commentaries, Editorials and Letters